Free Newsletter
Who should decide if a drug is worth the cost?
With our new President in office, the debate continues about America's seemingly unlimited spending on prescription medications and the best ways to control healthcare costs. Scott Gottlieb wrote an op-ed in the Wall Street Journal opposing the strategies he sees President Obama and the new administration considering to solve the problem. Report.
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: